HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jian Jin Selected Research

snake venom protein C activator

1/2022Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
1/2022A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells.
1/2022Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
1/2022EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis.
1/2021Cancer Selective Target Degradation by Folate-Caged PROTACs.
1/2021Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jian Jin Research Topics

Disease

110Neoplasms (Cancer)
03/2022 - 08/2009
33Breast Neoplasms (Breast Cancer)
10/2022 - 05/2006
12Inflammation (Inflammations)
01/2021 - 01/2011
11Fibrosis (Cirrhosis)
07/2022 - 08/2014
11Infections
05/2022 - 03/2004
11Carcinogenesis
01/2022 - 02/2014
8Neoplasm Metastasis (Metastasis)
02/2022 - 09/2013
7Diabetes Mellitus
03/2019 - 04/2013
6Leukemia
01/2022 - 01/2013
6Non-alcoholic Fatty Liver Disease
11/2021 - 04/2019
6Multiple Myeloma
01/2021 - 02/2016
5Triple Negative Breast Neoplasms
07/2022 - 04/2012
5Hepatocellular Carcinoma (Hepatoma)
11/2021 - 01/2014
5Fatty Liver
01/2021 - 01/2019
5Wounds and Injuries (Trauma)
11/2020 - 01/2015
5Melanoma (Melanoma, Malignant)
01/2020 - 09/2008
5Ovarian Neoplasms (Ovarian Cancer)
11/2017 - 09/2013
4Necrosis
07/2022 - 11/2018
4Mitochondrial Diseases (Mitochondrial Disease)
07/2022 - 01/2017
4Thyroid Neoplasms (Thyroid Cancer)
03/2022 - 01/2019
4Hyperglycemia
01/2021 - 01/2016
4Catalepsy
01/2021 - 11/2011
4Colonic Neoplasms (Colon Cancer)
08/2018 - 01/2014
4Colorectal Neoplasms (Colorectal Cancer)
11/2017 - 01/2015
3Ureteral Obstruction
07/2022 - 12/2020
3Cicatrix (Scar)
07/2022 - 12/2018
3Osteoporosis
03/2022 - 03/2013
3COVID-19
10/2021 - 11/2020
3Burns
01/2021 - 11/2018
3Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 05/2012
3Weight Gain
01/2021 - 09/2020
3Pain (Aches)
01/2021 - 05/2014
3Nasopharyngeal Carcinoma
01/2021 - 01/2019
3Insulin Resistance
01/2021 - 03/2019
3Schizophrenia (Dementia Praecox)
12/2020 - 02/2016
3Hypoxia (Hypoxemia)
01/2020 - 03/2015
3Hypertension (High Blood Pressure)
09/2019 - 11/2017
3Carcinoma (Carcinomatosis)
01/2018 - 08/2009

Drug/Important Bio-Agent (IBA)

44Proteins (Proteins, Gene)FDA Link
07/2022 - 05/2006
29Pharmaceutical PreparationsIBA
03/2022 - 10/2012
19Doxorubicin (Adriamycin)FDA LinkGeneric
06/2020 - 10/2012
12Histones (Histone)IBA
01/2022 - 08/2010
12ChromatinIBA
01/2022 - 09/2011
10Lysine (L-Lysine)FDA Link
01/2022 - 08/2010
9EnzymesIBA
10/2021 - 04/2018
9Biomarkers (Surrogate Marker)IBA
01/2021 - 04/2014
9Phosphotransferases (Kinase)IBA
01/2019 - 09/2008
9Paclitaxel (Taxol)FDA LinkGeneric
11/2017 - 09/2013
8MethyltransferasesIBA
01/2022 - 01/2011
8Polychlorinated Biphenyls (PCBs)IBA
01/2021 - 01/2019
7Polycomb Repressive Complex 2IBA
07/2022 - 01/2015
7Transcription Factors (Transcription Factor)IBA
01/2022 - 05/2006
7LigandsIBA
01/2022 - 08/2012
7Biological ProductsIBA
01/2020 - 10/2012
7Transient Receptor Potential ChannelsIBA
10/2017 - 10/2012
6MicroRNAs (MicroRNA)IBA
02/2022 - 05/2014
6snake venom protein C activatorIBA
01/2022 - 01/2021
6CytokinesIBA
01/2021 - 01/2014
6AnthracyclinesIBA
10/2018 - 10/2014
5CateninsIBA
07/2022 - 05/2015
5Arginine (L-Arginine)FDA Link
01/2021 - 01/2011
5taxaneIBA
10/2018 - 10/2014
5Tacrolimus (Prograf)FDA LinkGeneric
01/2018 - 01/2016
5Member 1 Subfamily B ATP Binding Cassette TransporterIBA
03/2015 - 10/2012
4Proteolysis Targeting ChimeraIBA
07/2022 - 01/2021
4Small Interfering RNA (siRNA)IBA
06/2022 - 01/2017
4DNA (Deoxyribonucleic Acid)IBA
01/2022 - 07/2015
4RNA (Ribonucleic Acid)IBA
01/2022 - 08/2017
4graphene oxideIBA
01/2021 - 01/2019
4ElementsIBA
01/2021 - 07/2016
4Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
01/2021 - 12/2011
4ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2014
4Histone MethyltransferasesIBA
11/2020 - 01/2014
4Phosphatidylinositols (Phosphatidylinositol)IBA
07/2019 - 05/2014
3Enhancer of Zeste Homolog 2 ProteinIBA
07/2022 - 01/2015
3DioxinsIBA
12/2021 - 04/2019
3UNC1999IBA
11/2021 - 01/2015
3Antiviral Agents (Antivirals)IBA
10/2021 - 03/2004
3Reactive Oxygen Species (Oxygen Radicals)IBA
02/2021 - 01/2017
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 04/2012
3Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA
01/2021 - 01/2020
3MicellesIBA
12/2020 - 01/2014
3Antipsychotic Agents (Antipsychotics)IBA
12/2020 - 11/2011
3Glucose (Dextrose)FDA LinkGeneric
02/2020 - 04/2013
3Messenger RNA (mRNA)IBA
01/2020 - 12/2015
3Adenosine Triphosphate (ATP)IBA
11/2019 - 01/2015
3Environmental Pollutants (Pollutants, Environmental)IBA
07/2019 - 01/2019
3Metformin (Glucophage)FDA LinkGeneric
03/2019 - 01/2016
3Sirolimus (Rapamycin)FDA Link
03/2019 - 01/2016
3Insulin (Novolin)FDA Link
03/2019 - 03/2017
3Cadherins (E-Cadherin)IBA
01/2019 - 10/2017
3Protein Isoforms (Isoforms)IBA
08/2018 - 03/2014
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2016 - 09/2012
3Dipeptidyl-Peptidase IV InhibitorsIBA
01/2016 - 01/2014

Therapy/Procedure

45Therapeutics
02/2022 - 04/2012
23Drug Therapy (Chemotherapy)
02/2022 - 10/2012
5Thyroidectomy
03/2022 - 01/2015
4Neoadjuvant Therapy
10/2022 - 04/2016
4Transplantation
01/2021 - 01/2016
3Hematopoietic Stem Cell Transplantation
01/2021 - 01/2017